Concentric Analgesicsincis A Clinical Stage Biopharmaceutical Company Based In San Franciscocaliforniafounded In 2014The Company Is Focused On Discovering And Developing Novelnon Opioid Therapeutics For Managing Both Acute And Chronic Painthis Mission Aligns With Global Efforts To Reduce Opioid Use And Improve Patient Outcomes The Company S Leading Product Candidatevocacapsaicinca 008 Is Designed For Managing Postsurgical Pain And Has Received Fast Track And Breakthrough Therapy Designations From The Fdaconcentric Analgesics Also Has Ongoing Development Programs Targeting Chronic Osteoarthritis Pain And Refractory Paintheir Proprietary Prodrug Therapeutics Convert To Capsaicinwhich Selectively Desensitizes Pain Conducting Nerve Fibers Without Causing Sensory Numbness Or Motor Weakness Concentric Analgesics Engages In Clinical Research Collaborationsincluding A Partnership With Evolution Research Group To Conduct Phase 3 Trials For Vocacapsaicinthe Company Has Secured Significant Funding To Support Its Research And Development Efforts And Is Led By Ceo Frank Bellizzi
